检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

I. Bondarenko,A. Sezer,S. Kilickap,M. Gumus,M. Ozguroglu, M. Gogishvili,H. M. Turk,I. Cicin,D. Bentsion,O. Gladkov, P. Clingan,V. Sriuranpong,N. Rizvi,J. Mcginniss,J. Pouliot,S. Lee,F. Seebach,I. Lowy,G. Gullo,P. Rietschel

JOURNAL OF THORACIC ONCOLOGY（2021）

引用 0|浏览3
暂无评分
关键词
Randomised Controlled Trials, Phase II and III Clinical Trials, Immune checkpoint inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要